BPC-157
Accelerates tissue healing and gut repair
- Gut Health
- Tendon/Ligament/Muscle Healing
- Anti-Inflammatory
No human clinical trials exist — all safety data is from animal studies Theoretical concern: pro-angiogenic effects may be contraindicated in active cancer or conditions where blood vessel growth is undesirable Not FDA-approved for any indication; sold only for research purposes Long-term effects in humans are completely unknown
Mechanism of Action
BPC-157 is a 15-amino acid peptide derived from human gastric juice that appears to modulate the nitric oxide (NO) system and interact with multiple growth factor pathways. It influences NO synthase activity, counteracting both NO system overactivation and blockade, while also affecting dopamine, serotonin, and GABA neurotransmitter systems. The peptide demonstrates angiogenic properties, promoting blood vessel formation and collateral circulation recruitment, which underlies many of its observed healing effects. Key Pathways: Nitric oxide (NO) system modulation - balances L-NAME and L-arginine effects, Angiogenesis and vascular recruitment - VEGFR, EGR, NOS gene expression, Neurotransmitter system interaction - dopamine, serotonin, GABA modulation, Oxidative stress reduction - decreases MDA (malondialdehyde) levels The NO system modulation and angiogenic effects help explain BPC-157's observed capacity to accelerate wound healing, restore blood flow to ischemic tissues, and protect gastrointestinal mucosa in animal models. Its ability to promote collateral circulation and reduce oxidative stress markers correlates with improved tissue repair in tendons, ligaments, muscles, and gut lining observed in rat studies. The neurotransmitter interactions may contribute to its apparent gastroprotective and stress-mitigating properties.
Common Dose Reference Ranges
Educational reference ranges only — discuss actual dosing with a qualified healthcare provider.
Full BPC-157 protocols — frequency, timing, cycle length, reconstitution & research
- Theoretical angiogenesis concern in active cancer contexts
- Lack of documented adverse effects in animal studies
- Unknown long-term effects
- Injection site reactions
- Gastrointestinal effects